<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117535">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736969</url>
  </required_header>
  <id_info>
    <org_study_id>MSM-RD-023</org_study_id>
    <nct_id>NCT01736969</nct_id>
  </id_info>
  <brief_title>A Substantial Equivalence Study of RD04723 and Predicate Device</brief_title>
  <official_title>Microcyn Scar Management HydroGel, K103163 vs. Kelo-coteÂ® Scar Gel for the Management of Hypertrophic or Keloid Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculus Innovative Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculus Innovative Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a developmental formulation is
      substantially equivalent to the predicate device in the treatment of hypertrophic and keloid
      scars.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison between groups in Vancouver Scar Scale total score from Baseline to Day 112 (or early termination)</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vascularity, height/thickness, pliability, and pigmentation. Scoring from zero to thirteen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and itch</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient assessment of pain and itch. Scoring from 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline, Weeks: 2, 4, 8, 12 and early termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>8 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient assessment (satisfaction) with scar treatment. Stated as: &quot;very good, good, moderate or unsatisfactory&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertrophic Scar</condition>
  <condition>Keloid Scar</condition>
  <arm_group>
    <arm_group_label>RD047-023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RD-047-023</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Predicate Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>legally marketed predicate device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RD047-023</intervention_name>
    <description>Experimental hydrogel</description>
    <arm_group_label>RD047-023</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Predicate Device</intervention_name>
    <arm_group_label>Predicate Device</arm_group_label>
    <other_name>Kelo-Cote</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent and release health information

          -  Ability to follow study instructions and study requirements

          -  Have a hypertrophic or keloid scar accessible for treatment and evaluation

          -  Negative pregnancy test for women of childbearing potential

          -  Agreement to use effective birth control method for study duration

        Exclusion Criteria:

          -  History of allergy or sensitivity to components

          -  History of diabetes

          -  History of collagen vascular disorders

          -  Anticipated need for surgery or hospitalization during the study

          -  Pregnant, nursing, or planning a pregnancy during the study

          -  Current enrollment in an investigational drug or device study or participation in
             such a study within the last 30 days prior to Baseline (Day 0)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet C DuBois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 30, 2012</lastchanged_date>
  <firstreceived_date>October 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Keloid</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
